Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.
J Virol
; 89(16): 8334-45, 2015 Aug.
Article
em En
| MEDLINE
| ID: mdl-26041300
ABSTRACT
Broadly neutralizing antibodies (bnAbs) can prevent lentiviral infection in nonhuman primates and may slow the spread of human immunodeficiency virus type 1 (HIV-1). Although protection by passive transfer of human bnAbs has been demonstrated in monkeys, durable expression is essential for its broader use in humans. Gene-based expression of bnAbs provides a potential solution to this problem, although immune responses to the viral vector or to the antibody may limit its durability and efficacy. Here, we delivered an adeno-associated viral vector encoding a simianized form of a CD4bs bnAb, VRC07, and evaluated its immunogenicity and protective efficacy. The expressed antibody circulated in macaques for 16 weeks at levels up to 66 g/ml, although immune suppression with cyclosporine (CsA) was needed to sustain expression. Gene-delivered simian VRC07 protected against simian-human immunodeficiency virus (SHIV) infection in monkeys 5.5 weeks after treatment. Gene transfer of an anti-HIV antibody can therefore protect against infection by viruses that cause AIDS in primates when the host immune responses are controlled.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Imunoglobulina G
/
Anticorpos Anti-HIV
/
Modelos Moleculares
/
Infecções por HIV
/
HIV-1
/
Anticorpos Neutralizantes
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Virol
Ano de publicação:
2015
Tipo de documento:
Article